4CPS-240 A QUALITATIVE STUDY ON HOW CLINICAL PHARMACISTS PERFORM MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT

^{1,2}MK Moan Ingebrigtsen*, ^{2,3}J Kutschera Sund, ¹M Winge, ⁴HT Bell. ¹Levanger Hospital Pharmacy, Central Norway Hospital Pharmacy Trust, Levanger, Norway; ²Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; ³Central Norway Hospital Pharmacy Trust, Central Norway Hospital Pharmacy Trust, Trondheim, Norway; ⁴Faculty of Nursing and Health Sciences, Nord University, Levanger, Norway

10.1136/ejhp-pharm-2019-eahpconf.389

Background An accurate drug history is an essential part of patient assessment at admission to hospital. Studies show that pharmacists obtain a more accurate medication history than other health professionals. In many countries clinical pharmacists work in the emergency department (ED) performing medication reconciliation (MR). Although many quantitative studies describe the effect of clinical pharmacists in the ED, to our knowledge, there are no qualitative studies on how clinical pharmacists perform MR and which factors they perceive to affect their work.

Purpose The aim of this study was to describe how clinical pharmacists perform MR in an ED and to identify barriers and factors influencing all steps of MR such as preparation, patient interview and documentation.

Material and methods The study was conducted in the ED in a hospital with 173 beds. A non-participating observational method was used and a standardised observation form was developed based on existing procedures. Seven hospital pharmacists were included and 61 MR were observed over 10 days. Based on the findings from the observation study, a semi-structured focus group interview with five hospital pharmacists was conducted. Data from the observation study was described in relation to the existing procedure, and together with data from the interview, analysed using Systematic Text Condensation.

Results Variations were observed and influencing factors identified and organised in three themes: the patient, the clinical pharmacist and the workflow in the ED.

The complexity of the patient's medication history affected how the pharmacists prepared for, and conducted, the interview. The patients' relatives and the general condition of the patient also had an impact on the questions asked.

The degree of clinical experience and training influenced the clinical pharmacists' decisions in all phases of the MR, as well as the clinical pharmacists' assertiveness.

The clinical pharmacy service was not fully integrated in the ED workflow, and although the clinical pharmacists felt integrated, they seemed to perform their service in parallel with other healthcare professionals.

Conclusion Several factors have an impact on how clinical pharmacists conduct MR in an ED and influence their choices. This study shows that the service provided by the clinical pharmacists are not optimal and should be further developed.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-241 DDI-PREDICTOR: A NOVEL CLINICAL PHARMACY DECISION-MAKING TOOL FOR DOSE ADAPTATION?

¹F Moreau*, ^{1,2}N Simon, ^{3,4}M Tod, ^{1,2}B Decaudin, ^{1,2}P Odou. ¹CHU Lille, institut de pharmacie, lille, france; ²Univ. Lille, EA 7365 – Grita – Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France; ³Université Lyon 1- Faculté de Médecine Lyon-Sud-Charles Mérieux, Emr 3738, Oullins, France; ⁴Groupement Hospitalier Nord- Hospices Civils de Lyon, Pharmacy, Lyon, France

10.1136/ejhp-pharm-2019-eahpconf.390

Background To date, pharmacists have been limited to advising physicians about changes in drug prescriptions in the case of drug-drug interactions (DDI), cirrhosis or the presence of genetic polymorphism on P450 cytochromes (CYP). Dose adaptation is complicated. DDI-Predictor (DDI-P) is a free online application composed of five modules. Three modules are: drug-drug interaction; drug exposure level in case of cirrhosis; and drug exposure level in case of genetic polymorphism for CYP2D6, 2 C9 and 2 C19. The other two modules are combinations of the previous three modules, namely (a) + (b) or (a) + (c).

Purpose To describe DDI-P use as a clinical pharmacy decision-making tool.

Material and methods Eighteen clinical pharmacists were trained before using DDI-P. DDI-P computed a ratio of area under the drug-concentration curves (R_{AUC}) by comparing an AUC to a standard. Dose adaptation was calculated from R_{AUC} . Pharmaceutical intervention (PI) was advised if $0.5 \leq R_{AUC}$ (induction) or $R_{AUC} \geq 1.5$ (inhibition). Data recorded in a standardised datasheet in Excel software (Microsoft, France) were: date, drug and posology, interacting drug, cirrhosis grade, module used, R_{AUC} , PI and medical acceptance (MA). Data were analysed by one referent pharmacist. The endpoints were pharmaceutical intervention and medical acceptance rates.

Results 1 99 733 prescriptions were analysed during 26 months and 290 cases involved DDI-P. Seventy-seven cases were excluded (infructuous research, $n=43$; application misuse, $n=30$; uninterpretable results, $n=4$). Other cases concerned DDI with inducers ($n=56$; 26%) or inhibitors ($n=145$; 68%) and cirrhotic patients ($n=12$). PI occurred in 121 cases (56.8%), for inducers (75%), for inhibitors (54%) and for cirrhosis (66%). For inducers with $0.5 \leq R_{AUC}$, PI concerned: drug switch (33%) and interactor stop (6%). For inhibitors with $R_{AUC} \geq 1.5$, PI were dose-lowering (17/79) or drug switch (7/79). The MA rates were 88% and 82% for inducers and inhibitors, and 100% for cirrhosis, respectively.

Conclusion This first study assessing DDI-P shows how it may help clinical pharmacists in their daily practice. R_{AUC} value leads pharmacists to assess the importance of DDI and to propose therapeutic adjustments to physicians, contributing to therapeutic decisions. Although it is easy to use, pharmacists must therefore be trained to interpret the result in the clinical context at the time of the analysis to avoid potential misuses.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.